TY - JOUR
T1 - Emerging Treatments in Episodic Migraine
AU - Grimsrud, Kate W.
AU - Halker Singh, Rashmi B.
N1 - Publisher Copyright:
© 2018, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2018/9/1
Y1 - 2018/9/1
N2 - Purpose of Review: The purpose of this review is to evaluate and describe recent and emerging treatment options for episodic migraine. Recent Findings: Recent advances have been made in better understanding the pathophysiology of migraine, which has led to further investigation of potential new pharmacologic and non-pharmacologic treatment options. Summary: A number of new medications are emerging for the acute and preventive treatment of migraine, including CGRP monoclonal antibodies, CGRP receptor antagonists, serotonin 5-HT1F agonists, and PACAP receptor monoclonal antibodies. Additionally, newer studies on existing non-invasive neuromodulation devices including transcranial magnetic stimulation, supraorbital transcutaneous nerve stimulation, and transcutaneous vagus nerve stimulation have recently received FDA approval for use in migraine. Neuromodulation devices including percutaneous mastoid electrical stimulation, non-painful remote electrical stimulation, and caloric vestibular stimulation are undergoing further investigation and have shown promising results thus far. These new developments are expected to contribute to better treatment and decreased disability in migraine.
AB - Purpose of Review: The purpose of this review is to evaluate and describe recent and emerging treatment options for episodic migraine. Recent Findings: Recent advances have been made in better understanding the pathophysiology of migraine, which has led to further investigation of potential new pharmacologic and non-pharmacologic treatment options. Summary: A number of new medications are emerging for the acute and preventive treatment of migraine, including CGRP monoclonal antibodies, CGRP receptor antagonists, serotonin 5-HT1F agonists, and PACAP receptor monoclonal antibodies. Additionally, newer studies on existing non-invasive neuromodulation devices including transcranial magnetic stimulation, supraorbital transcutaneous nerve stimulation, and transcutaneous vagus nerve stimulation have recently received FDA approval for use in migraine. Neuromodulation devices including percutaneous mastoid electrical stimulation, non-painful remote electrical stimulation, and caloric vestibular stimulation are undergoing further investigation and have shown promising results thus far. These new developments are expected to contribute to better treatment and decreased disability in migraine.
KW - Calcitonin gene-related peptide
KW - Episodic migraine
KW - Neuromodulation
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=85050082298&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050082298&partnerID=8YFLogxK
U2 - 10.1007/s11916-018-0716-2
DO - 10.1007/s11916-018-0716-2
M3 - Review article
C2 - 30014208
AN - SCOPUS:85050082298
SN - 1531-3433
VL - 22
JO - Current pain and headache reports
JF - Current pain and headache reports
IS - 9
M1 - 61
ER -